We are live on ! Find out more
ASND icon

Ascendis Pharma A/S

203 hedge funds and large institutions have $8.28B invested in Ascendis Pharma A/S in 2024 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 75 increasing their positions, 67 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

65% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 23

12% more repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 67

7% more funds holding

Funds holding: 189203 (+14)

6% more funds holding in top 10

Funds holding in top 10: 1617 (+1)

0.19% less ownership

Funds ownership: 105.35%105.16% (-0.19%)

10% less capital invested

Capital invested by funds: $9.19B → $8.28B (-$914M)

52% less call options, than puts

Call options by funds: $21.1M | Put options by funds: $43.9M

Holders
203
Holders Change
+14
Holders Change %
+7.41%
% of All Funds
2.93%
Holding in Top 10
17
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+6.25%
% of All Funds
0.25%
New
38
Increased
75
Reduced
67
Closed
23
Calls
$21.1M
Puts
$43.9M
Net Calls
-$22.8M
Net Calls Change
-$19.3M
Name Holding Trade Value Shares
Change
Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$1.38B
Westfield Capital Management
2
Westfield Capital Management
Massachusetts
$677M +$121M +887,610 +22%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$671M -$2.16M -15,906 -0.3%
Artisan Partners
4
Artisan Partners
Wisconsin
$586M -$187M -1,376,905 -24%
ACA
5
Avoro Capital Advisors
New York
$572M +$31.3M +229,995 +6%
Janus Henderson Group
6
Janus Henderson Group
United Kingdom
$534M +$20.6M +151,610 +4%
Wellington Management Group
7
Wellington Management Group
Massachusetts
$356M -$18.1M -133,016 -5%
Capital International Investors
8
Capital International Investors
California
$287M -$11.8M -87,014 -4%
Franklin Resources
9
Franklin Resources
California
$284M +$14M +102,982 +5%
T. Rowe Price Associates
10
T. Rowe Price Associates
Maryland
$243M +$302K +2,222 +0.1%
Massachusetts Financial Services
11
Massachusetts Financial Services
Massachusetts
$233M +$12.7M +93,185 +6%
Invesco
12
Invesco
Georgia
$151M +$19.3M +141,786 +15%
Adage Capital Partners
13
Adage Capital Partners
Massachusetts
$112M +$83.1M +611,000 +292%
VPC
14
Vestal Point Capital
New York
$102M +$30.6M +225,000 +43%
SI
15
Sofinnova Investments
California
$100M -$2.69M -19,748 -3%
PBA
16
Paradigm Biocapital Advisors
New York
$90.6M +$21.3M +156,355 +31%
SCM
17
Spyglass Capital Management
California
$90.4M +$6.64M +48,781 +8%
Ameriprise
18
Ameriprise
Minnesota
$90.1M +$82.4M +605,496 +1,098%
TCM
19
TimesSquare Capital Management
New York
$81.3M +$2.81M +20,616 +4%
Citadel Advisors
20
Citadel Advisors
Florida
$73.3M +$10.9M +80,258 +18%
Brown Advisory
21
Brown Advisory
Maryland
$65.3M -$27.9M -205,396 -30%
AllianceBernstein
22
AllianceBernstein
Tennessee
$64.8M +$170K +1,248 +0.3%
Millennium Management
23
Millennium Management
New York
$64.6M +$15.2M +111,389 +31%
Fidelity International
24
Fidelity International
Bermuda
$60.3M +$58.7M +431,781 +4,025%
Goldman Sachs
25
Goldman Sachs
New York
$57.5M -$2.11M -15,541 -4%

ASND Hedge Fund Activity: Q2 2024 in Review

203 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q2 2024, worth a combined $8.28B — down 9.9% from $9.19B a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new ASND positions and 23 closed out — a net gain of 15 holders — while 75 added to existing stakes and 67 trimmed.

The largest buyer was Westfield Capital Management, adding an estimated $121M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $345M.

  • 203 institutional investors held Ascendis Pharma A/S (ASND) as of Q2 2024, up from 189 in Q1 2024.
  • Funds reported $8.28B of Ascendis Pharma A/S stock for Q2 2024, down 9.9% quarter-over-quarter.
  • 38 funds opened new Ascendis Pharma A/S positions in Q2 2024 and 23 closed out, a net change of +15 holders.
  • The largest Ascendis Pharma A/S buyer in Q2 2024 was Westfield Capital Management, an estimated $121M added.
  • The largest Ascendis Pharma A/S seller in Q2 2024 was T. Rowe Price Investment Management, an estimated $345M sold.

Based on aggregated 13F filings for Q2 2024.